Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELATIVITY-123: Nivolumab-relatlimab FDC vs Regorafenib or TAS-102 in Later-lines of Metastatic Colorectal Cancer
NCT05328908Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 22
01
Overview
A Phase 3 trial of nivolumab + relatlimab in colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started Apr 2022; status: terminated.
02
Drugs
nivolumab + relatlimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05328908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328908.